Aurobindo Pharma Profile
Key Indicators
- Authorised Capital ₹ 666.40 Cr
as on 07-08-2024
- Paid Up Capital ₹ 58.59 Cr
as on 07-08-2024
- Company Age 38 Year, 28 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2,015.00 Cr
as on 07-08-2024
- Satisfied Charges ₹ 4,387.54 Cr
as on 07-08-2024
- Revenue 10.60%
(FY 2023)
- Profit -15.42%
(FY 2023)
- Ebitda 17.48%
(FY 2023)
- Net Worth 4.66%
(FY 2023)
- Total Assets 15.43%
(FY 2023)
About Aurobindo Pharma
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524804 and on the National Stock Exchange(NSE) under AUROPHARMA.
The Corporate was formerly known as Aurobindo Pharma Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 666.40 Cr and a paid-up capital of Rs 58.59 Cr.
The company currently has active open charges totaling ₹2,015.00 Cr. The company has closed loans amounting to ₹4,387.54 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Aurobindo Pharma Ltd India are Mr Reddy as COMPANY SECRETARY and Mr Ssubramanian as Cfo. Venkata Penaka, Nityananda Kambam, Madan Mettu, and Seven other members serve as directors at the Company.
- CIN/LLPIN
L24239TG1986PLC015190
- Company No.
015190
- Stock Symbol
BSE : 524804 NSE : AUROPHARMA
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Dec 1986
- Date of AGM
25 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aurobindo Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mr Reddy  | Company Secretary | Current | |
| Mr Ssubramanian | CFO | Current | |
| Nityananda Kambam | Managing Director | 30-Dec-1992 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Savita Mahajan | Director | 16-Dec-2017 | Current |
| Santanu Mukherjee | Director | 21-Mar-2023 | Current |
| Deepali Joshi | Director | 04-Mar-2024 | Current |
| Venkata Penaka | Director | 30-Dec-1992 | Current |
| Madan Mettu | Whole-Time Director | 01-Jan-2013 | Current |
| Sarath Penaka | Director | 27-Sep-2007 | Current |
Financial Performance of Aurobindo Pharma.
Aurobindo Pharma Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 10.6% increase. The company also saw a substantial fall in profitability, with a 15.42% decrease in profit. The company's net worth moved up by a moderate rise of 4.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aurobindo Pharma?
In 2023, Aurobindo Pharma had a promoter holding of 51.84% and a public holding of 48.17%. The company had 18 Subsidiaries and 2 Joint Ventures. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Export-Import Bank Of India Creation Date: 23 Dec 1999 | ₹15.00 Cr | Open |
State Bank Of India Creation Date: 05 Jun 1997 | ₹2,000.00 Cr | Open |
Dbs Bank Ltd Creation Date: 08 Jan 2013 | ₹164.00 Cr | Satisfied |
How Many Employees Work at Aurobindo Pharma?
Aurobindo Pharma has a workforce of 15925 employees as of Aug 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aurobindo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurobindo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
